We love to answer reader questions, so send yours to HC@Fool.com. Here's a recent submission to our mailbag:
The NBA draft lottery was last night and Cleveland won the first overall pick again. If you were drafting a drug in development for your biotech, what would be your #1 pick. Go Cavs!
In this episode of The Motley Fool's health-care show Market Checkup, analysts David Williamson and Michael Douglass answer Keith's question. After Michael selected an immuno-oncology headline maker, David responds by drafting a boom-or-bust product with possibly the highest ceiling imaginable, Biogen's (NASDAQ:BIIB) Alzheimer's drug BIIB037.
However, for all its potentia,l BIIB037 is surrounded by red flags. Watch and find out what they are and why David likes the drug enough to draft it No. 1 overall.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Ford's Tumultuous 2017
Ford’s stock languished behind GM throughout 2017. Will 2018 be a turnaround year?
Intel Corp. Is Now Sampling XMM 7560 LTE Modem
The tech titan seems to be on track with its next-generation cellular modem.
3 Disruptive Stocks That Justify Their High Valuations
For long-term holders, it pays to pay up for disruptive potential.